Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
IPO Year: 2014
Exchange: NASDAQ
Website: bellicum.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/16/2022 | $5.00 | Buy | Ladenburg Thalmann |
15-12G - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
8-K - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
POS AM - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
POS AM - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
3 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13D/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13D - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13D - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company's assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most recent patient treated in the Phase 1/2 trial of BPX-601 in metastatic castration-resistant prostate cancer (mCRPC) experienced serious immune-mediated adverse events including Grade 4 cytokine rel
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and bone involvement HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled "Early Results from a Phase 1, Multicent
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.14 per share and vest over four years, with 25% of the shares vesting on the one-year a
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held February 16-18, 2023 in San Francisco and virtually. The ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer. Details of the poster presentation are as follows: Title: Early Results from a
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) team at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held in New Orleans December 10-13, 2022. The presentation, scheduled for today at 6 p.m. CT, will provide data on four patients who received rimiducid to activate the CaspaCIDe® safety switch in an investigator sponsored trial. The poster titled "Abrogation of Immune Effector Cell Neurotoxicity Syndrome (
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update. "We are encouraged by the progress we are making in our patient enrollment efforts for the BPX-601 and BPX-603 trials despite a national fludarabine shortage, and are on track to present data updates for both programs in the first half of 2023," said Rick Fair, President and Chief Executive Officer. "We are also excited about new data from the Baylor College of Medicine supporting the potential benefit of CaspaCIDe® in resolvin
HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 31, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.06 per share and vest over four years, with 25% of the shares vesting on the one-year a
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally. Details regarding Bellicum's presentation at the conference are as follows: Event: 2022 Cell & Gene Meeting on the Mesa Date: October 11, 2022Time: 4:30 p.m. PT Location: Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011 Virtual attendance is available which includes a livestream of Bellicum's presentation and the ability to v
HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 70,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of September 30, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.20 per share and vest over four years, with 25% of the shares vesting on the one-yea
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website. About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The comp
Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals with a rating of Buy and set a new price target of $5.00
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief Development Officer effective December 1, 2021 - HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2021 and provided an operational update. "In the third quarter, Bellicum broadened the potential impact of its CaspaCIDe technology through an additional licensing agreement with MD Anderson," said Rick Fair, President and